TABLE 2.
Comparison of Clinical Parameters between Baseline and SO Therapy (258 PD Patients)
| Parameter | Baseline | SO follow-up | P-value |
|---|---|---|---|
| Phosphate binder pills/day* | 10.0 (0.2) | 4.3 (0.2) | <0.0001 |
| Mineral and bone disease markers | |||
| Serum phosphorus (mg/dL) | 6.59 (0.09) | 6.26 (0.09) | <0.0001 |
| Albumin-corrected calcium (mg/dL) | 9.36 (0.04) | 9.31 (0.04) | 0.018 |
| Intact PTH (pg/mL) | 468 (23) | 497 (22) | 0.032 |
| Nutritional and clearance parameters | |||
| Weight (kg) | 86.8 (1.5) | 86.9 (1.5) | 0.8 |
| Serum albumin (g/dL) | 3.70 (0.02) | 3.62 (0.02) | <0.0001 |
| Phosphorus-attuned albumin (×103) | 0.6 (0.01) | 0.63 (0.01) | <0.0001 |
| nPCR (g/kg/day) | 1.0 (0.03) | 1.0 (0.02) | 0.9 |
| Phosphorus-attuned nPCR (×103 dL/kg/day) | 0.17 (0.005) | 0.18 (0.004) | 0.044 |
| Serum creatinine (mg/dL) | 12.0 (0.3) | 12.2 (0.3) | 0.001 |
| Kru (mL/min/1.73 m2) | 2.85 (0.20) | 2.47 (0.19) | 0.008 |
| PD Kt/V | 1.65 (0.05) | 1.70 (0.04) | 0.5 |
| Total Kt/V | 2.1 (0.06) | 2.1 (0.05) | 0.7 |
| Anemia and iron indices | |||
| Patients not receiving IV iron therapy (n=93) | |||
| Ferritin (ng/mL) | 801 (66) | 876 (65) | 0.018 |
| Transferrin saturation (%) | 38.5 (1.4) | 38.5 (1.3) | 0.9 |
| Hemoglobin (g/dL) | 11.2 (0.2) | 11.3 (0.2) | 0.039 |
| Iron (mcg/dL) | 98.1 (3.5) | 93.2 (3.2) | 0.077 |
| Patients receiving IV iron therapy (n=165) | |||
| Ferritin (ng/mL) | 748 (36) | 940 (34) | <0.0001 |
| Transferrin saturation (%) | 34.0 (0.9) | 38.4 (0.8) | <0.0001 |
| Hemoglobin (g/dL) | 10.6 (0.1) | 10.7 (0.1) | 0.078 |
| Iron (mcg/dL) | 85.8 (2.4) | 92.3 (2.1) | 0.005 |
Values are expressed as least-squared means (standard error), p-values compare least-squared means between treatment periods.
Abbreviations: Kru- residual urea clearance; nPCR - normalized protein catabolic rate; PD – peritoneal dialysis; PTH - parathyroid hormone; SO – sucroferric oxyhydroxide
*
Pill burden at baseline was calculated only for patients who received phosphate binder prescriptions through FreseniusRx (n=92). Follow-up PB pill burden for patients with no baseline binder available through FreseniusRx (n=166) was found to be 4.3 SO pills/day